Barclays
DMAC icon

Barclays’s DiaMedica Therapeutics DMAC Stock Holding History

Barclays’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.5K Buy
13,145
+6,658
+103% +$40.9K ﹤0.01% 4071
2026
Q1 		$43.9K Sell
6,487
-46,424
-88% -$368K ﹤0.01% 4366
2025
Q4 		$421K Buy
52,911
+7,471
+16% +$55.9K ﹤0.01% 3935
2025
Q3 		$312K Sell
45,440
-3,333
-7% -$18.1K ﹤0.01% 4070
2025
Q2 		$190K Buy
48,773
+30,503
+167% +$119K ﹤0.01% 4313
2025
Q1 		$69.2K Sell
18,270
-9,456
-34% -$54.1K ﹤0.01% 4521
2024
Q4 		$151K Buy
+27,726
New +$131K ﹤0.01% 4430
2021
Q4 		– Sell
-4,616
Closed -$19K – 4231
2021
Q3 		$19K Buy
4,616
+3,208
+228% +$12.3K ﹤0.01% 4404
2021
Q2 		$6K Sell
1,408
-2,004
-59% -$16.4K ﹤0.01% 4728
2021
Q1 		$31K Buy
+3,412
New +$31.9K ﹤0.01% 4292

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Barclays's DMAC Position: Q2 2026 in Review

Barclays increased its DiaMedica Therapeutics (DMAC) stake by 103% in Q2 2026, buying an estimated $40.9K and bringing the position to 13,145 shares worth $92.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4071.

Barclays first reported a position in DMAC in Q1 2021 and has held it in 10 quarters since. The position peaked at $421K in Q4 2025. 88 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Barclays held 13,145 shares of DiaMedica Therapeutics worth $92.5K as of Q2 2026.
  • Barclays bought 6,658 DiaMedica Therapeutics shares in Q2 2026, an estimated $40.9K.
  • DiaMedica Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4071 holding.
  • Barclays first reported a position in DiaMedica Therapeutics in Q1 2021 and has held it in 10 quarters since.
  • Barclays's DiaMedica Therapeutics position peaked at $421K in Q4 2025.
  • 88 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.